Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine

Headache

Volumn 36, Issue 3, 1996, Pages 137-143

  Mushet, George R ^a   Miller, David ^b   Clements, Bill ^b   Pait, Gayla ^b   Gutterman, Donna L ^b  

^a Georgia Headache Treatment Center   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

headache; migraine; productivity; quality of life; sumatriptan

Indexed keywords

ACETYLSALICYLIC ACID; BUTALBITAL; CAFFEINE; CODEINE; DEXTROPROPOXYPHENE; DICHLORALPHENAZONE; IBUPROFEN; ISOMETHEPTENE; PARACETAMOL; PLACEBO; PROMETHAZINE; SEROTONIN 1 AGONIST; SUMATRIPTAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HOSPITAL PERSONNEL; HUMAN; JOB PERFORMANCE; MALE; MIGRAINE; NAUSEA; NECK PAIN; NOSE DISEASE; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; SUBCUTANEOUS DRUG ADMINISTRATION; THORAX PAIN; VOMITING; WORKPLACE;

ACTIVITIES OF DAILY LIVING; ADULT; EFFICIENCY; EMPLOYEE PERFORMANCE APPRAISAL; FEMALE; GEORGIA; HUMANS; MALE; MIGRAINE DISORDERS; PERSONNEL, HOSPITAL; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SEROTONIN AGONISTS; SICK LEAVE; SUMATRIPTAN;

EID: 0029922814     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.1996.3603137.x     Document Type: Article

References (20)

1. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache. 1993;33:29-35.
2. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267:64-69.
3. de Lissovoy G, Lazarus SS. The economic cost of migraine. Present state of knowledge. Neurology. 1994;44(suppl 4):S56-S62.
4. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics. 1992;2:67-76.
5. Solomon GD, Skobieranda FG, Gragg LA. Quality of life and well-being of headache patients: measurement by the Medical Outcomes Study instrument. Headache. 1993;33:351-358.
6. Dahlof C. Assessment of health-related quality of life in migraine. Cephalalgia. 1993; 13:233-237.
7. Osterhaus JT, Townsend RJ, Gandek B, Ware JE Jr. Measuring the functional status and well-being of patients with migraine headache. Headache. 1994;34:337-343.
8. Ware JE Jr. SF-36 Health Survey Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center Hospitals, Inc; 1993.
9. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
10. Prevalence of chronic migraine headaches- United States, 1980-1989. MMWR Morb Mortal Wkty Rep. 1991;40:331.
11. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325:316-321.
12. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265:2831-2835.
13. Schoenen J, Bulcke J, Caekebeke J, et al. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study. Cephalalgia. 1994;14:55-63.
14. The Sumatriptan Auto-Injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol. 1991;31:323-331.
15. Headache Classification Committee of the International Headache Society- Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-98.
16. Reilly MC, Zbiozek AS, Dukes EM. The validity and reproducibility of a workplace productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353-365.
17. Miller DW, Kirchdoerfer LJ, Shepherd MD, et al. A disease-specific instrument to measure quality of life effects attributable to migraine. Presented at the Health Services Research Association 10th Annual Meeting; June 27-29, 1993; Washington, DC.
18. Kozma CM, Mauch RP, Reeder CE, Lawrence BJ. A literature review comparing the economic, clinical, and humanistic attributes of dihydroergotamine and sumatriptan. Clin Ther. 1994;16:1037-1051.
19. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis. 1993;147:832838.
20. Jhingran P, Grice RB, Miller DW, Gutterman DL. Assessment of health-related quality of life, disability, and productivity in migraine patients exposed and unexposed to sumatriptan. Presented at the Annual Meeting of the American Public Health Association; October 30 - November 3, 1994; Washington, DC.